Compounds > lopinavir
Page last updated: 2024-08-26

lopinavir and Coronary Disease

lopinavir has been researched along with Coronary Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
En Liew, LQ; Liew, MF; Shree, V; Teo, WW; Ting, J1
Dietz, B; Rajagopalan, R; Simpson, KN1
Brun, S; Chumney, EC; King, MS; Luo, MP; Simpson, KN1
Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN2

Other Studies

5 other study(ies) available for lopinavir and Coronary Disease

ArticleYear
Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19 patient.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2021, Volume: 54, Issue:1

    Topics: Aged; Antiviral Agents; Bradycardia; Comorbidity; Coronary Disease; COVID-19 Drug Treatment; Drug Combinations; Humans; Hypertension; Lopinavir; Male; Ritonavir

2021
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
    Advances in therapy, 2009, Volume: 26, Issue:2

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Budgets; CD4 Lymphocyte Count; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Lopinavir; Markov Chains; Models, Econometric; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Smoking; United States

2009
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Clinical drug investigation, 2007, Volume: 27, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Fees, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; Survival Rate; Time Factors

2007
Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
    Clinical drug investigation, 2007, Volume: 27, Issue:7

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coronary Disease; Costs and Cost Analysis; Data Collection; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Markov Chains; Models, Statistical; Pyrimidinones; Quality of Life; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; United States; Viral Load

2007
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
    Clinical drug investigation, 2007, Volume: 27, Issue:12

    Topics: Adult; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; France; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Lopinavir; Male; Markov Chains; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Risk Factors; Ritonavir; Spain; Time Factors; United Kingdom

2007